Hemostemix Inc. (CVE:HEM – Get Free Report) shares fell 3.3% during mid-day trading on Thursday . The company traded as low as C$0.05 and last traded at C$0.06. 97,800 shares changed hands during mid-day trading, an increase of 77% from the average session volume of 55,264 shares. The stock had previously closed at C$0.06.
Hemostemix Trading Up 10.0%
The business has a fifty day simple moving average of C$0.07 and a 200-day simple moving average of C$0.08. The company has a debt-to-equity ratio of -72.45, a quick ratio of 0.48 and a current ratio of 0.49. The firm has a market cap of C$10.88 million, a price-to-earnings ratio of -1.90 and a beta of 0.59.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Stories
- Five stocks we like better than Hemostemix
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
- MarketBeat Week in Review – 05/18 – 05/22
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
